Vinay Tumuluri, MD
Internal Medicine · la Porte, INNPI 1528015344
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 1,458 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,458 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$2K
- Amgen$1K
- Pfizer$1K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- plus $14K from 54 others
What the payments were for
- Food & beverage$23,012100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$267
- KRYSTEXXA$250
- SOLIQUA 100/33$125
- PURIFIED CORTROPHIN GEL$125
- JARDIANCE$125
- Inpefa$123
How this compares
$23,042 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 246 | $399,696 |
| JardianceEmpagliflozin | 196 | $265,772 |
| OzempicSemaglutide | 170 | $250,428 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 163 | $215,791 |
| EliquisApixaban | 161 | $181,298 |
| TrulicityDulaglutide | 105 | $178,987 |
| XareltoRivaroxaban | 73 | $88,146 |
| FarxigaDapagliflozin Propanediol | 71 | $78,381 |
| VraylarCariprazine Hcl | 38 | $69,144 |
| Tresiba Flextouch U-100Insulin Degludec | 103 | $67,539 |
| RybelsusSemaglutide | 28 | $52,737 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $47,016 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $46,759 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $41,468 |
| MyrbetriqMirabegron | 45 | $40,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,171 | $586,382386 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $1,213 | $324,427238 claims |
| Novo NordiskOzempic, Rybelsus | $1,630 | $303,165198 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $801 | $262,806227 claims |
| PfizerEliquis, Nurtec Odt | $1,225 | $206,362176 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,202 | $92,51693 claims |
| AbbVieVraylar, Linzess, Savella | $2,629 | $89,66561 claims |
| Johnson & JohnsonXarelto | $523 | $88,14673 claims |
| Astellas Pharma US IncMyrbetriq | $298 | $40,09245 claims |
| NovartisEntresto | $707 | $29,88423 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $420 | $13,94918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in la Porte
- Joseph Arulandula Porte$251K
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.